This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Setting
The setting was secondary care. The economic study was carried out in New York, USA.
Dates to which data relate
The data were compiled from Cardiothoracic Division records, the transfusion service, the hospital finance office, a laboratory information system and written medical records. The effectiveness data were collected from July to December 1997 for the control group and from July to December 1998 for the intervention group. The cost data were obtained from the hospital finance department. These appear to have been collected at the same time as the effectiveness data.
Source of effectiveness data
The effectiveness data were derived from a single study.
Link between effectiveness and cost data
It appears that costing has been undertaken prospectively on the same patient sample as that used in the effectiveness study.
Study sample
The sample size was not determined in the planning stage of the study. Details of the sample selection process were not given, although the authors stated that the analysis included approximately 50% of the 650 patients who underwent open-heart surgery during the study period. The authors did not provide details of patients who refused to participate in the study, or were excluded. However, the authors stated that 12 patients in 1997 and 11 in 1998 were excluded from the analysis because they had received intraoperative salvage. There appear to have been 386 patients starting the trial, of which 204 were in the historical control group and 182 in the intervention group.
Study design
This was a comparative study with historical controls that was carried out in a single centre. The data were collected for 6 months (July to December 1997 for the controls and July to December 1998 for the intervention group). The loss to follow-up was not reported.
Analysis of effectiveness
The primary health outcomes used were: the number of hours in intensive care, the number of hours of ventilator use, the number of days of antibiotic therapy, the number of days with fever, and the number of deaths during hospitalisation.
The study did not specify which (if any) instruments were used to evaluate the data. It appears that all the patients included in the study have been accounted for in the analysis. The groups were comparable at baseline.
Effectiveness results
For transfusion recipients in the 1997 cohort, the length of stay (LOS) was 15.1 (standard deviation, SD=22.1) days. These patients spent 118 (SD=385) hours in the intensive care unit (ICU) and 80 (SD=35) hours on ventilation. They also had 6.7 (SD=22) days of antibiotic therapy and spent 6.9 (SD=11) days with fever. During hospitalisation, 5.3% of these patients died.
For transfusion recipients in the 1998 cohort, the LOS was 12.4 (SD=12.6) days. These patients spent 81 (SD=162) hours in the ICU and 33 (SD=120) hours on ventilation. They had also 4.6 (SD=10) days of antibiotic therapy and spent 5.4 (SD=6) days with fever. During hospitalisation, 3.2% of these patients died.
For patients in the 1997 cohort who did not receive transfusion, the LOS was 6.2 (SD=2.8) days. These patients spent 22 (SD=6.4) hours in the ICU and 7.0 (SD=4.6) hours on ventilation. They also had 0.24 (SD=1.0) days of antibiotic therapy and spent 2.5 (SD=1.7) days with fever. No patients died in hospital.
For patients in the 1998 cohort who did not receive transfusion, the LOS was 5.7 (SD=2.0) days. These patients spent 22 (SD=7.1) hours in the ICU and 4.2 (SD=2.0) hours on ventilation. They also had 0.32 (SD=1.5) days of antibiotic therapy and spent 3.3 (SD=1.5) days with fever. No patients died in hospital.
Clinical conclusions
The implementation of leukocyte reduction for all transfusion patients undergoing cardiac surgery resulted in reductions in the LOS, hours in intensive care, ventilator use, antibiotic therapy, fever and deaths during hospitalisation.
Direct costs
The total charges and costs from the perspective of the hospital were reported. The costs were estimated from detailed accounting by the hospital finance department, which included actual variable expenses, exclusive of overheads that occurred for all the study patients. Resource use and the unit costs were not reported separately. Discounting was not relevant because the time horizon of the study was less than 2 years, and was not undertaken. The historical control data for the intervention group related to 1997 and 1998. The price years were 1997 and 1998 (no correction for inflation was carried out).
Statistical analysis of costs
Descriptive statistics were given in the form of SDs.
Indirect Costs
No indirect costs were included in the analysis.
Currency

US dollars ($).
Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
For the transfusion recipients in the 1997 cohort, the total charges were $46,000 (SD=56,800) and the total costs were $29,000 (SD=36,300).
For the transfusion recipients in the 1998 cohort, the total charges were $40,900 (SD=39,300) and the total costs were $28,200 (SD=25,100).
For the patients in the 1997 cohort who did not receive transfusion, the total charges were $22,500 (SD=2,500) and the total costs were $14,800 (SD=3,800).
For the patients in the 1998 cohort who did not receive transfusion, the total charges were $22,400 (SD=10,600) and the total costs were $18,800 (SD=10,800).
Synthesis of costs and benefits
The costs and benefits were not combined.
Authors' conclusions
Leukocyte-reduced transfusions in cardiac surgery are associated with decreased costs of care, and may also reduce mortality.
